K 03861

Overview
Catalog #	bs-7190c-2mg-solid
Product Name	K 03861
Specifications
Storage Buffer	Powder
Storage Condition	Store in dry, dark place at -20C for 1 year.
Target
Product Information	Molecular Weight: 501.5 Formula: C24 H26 F3 N7 O2 CAS Number: 853299-07-7 InChi Key: PWDLXPJQFNVTNL-UHFFFAOYSA-N InChi: InChI=1S/C24H26F3N7O2/c1-33-10-12-34(13-11-33)15-16-2-3-18(14-20(16)24(25,26)27)31-23(35)30-17-4-6-19(7-5-17)36-21-8-9-29-22(28)32-21/h2-9,14H,10-13,15H2,1H3,(H2,28,29,32)(H2,30,31,35) Smiles: CN1CCN(CC2=CC=C(C=C2C(F)(F)F)NC(=O)NC2C=CC(=CC=2)OC2=CC=NC(N)=N2)CC1 Purity: 98.0 Solubility: Soluble in DMSO, not in water Appearance: Solid Power. Shelf Life: 1.0 years
Description	K 03861is a potent and selective Type II FLT3 inhibitor. K 03861 is able to override drug resistance that less potent "type I" inhibitors and "type II" first-generation FLT3 inhibitors cannot. Constitutively activated mutant FLT3 has emerged as a promising target for therapy for the subpopulation of acute myeloid leukemia (AML) patients who harbor it. The small molecule inhibitor, PKC412, targets mutant FLT3 and is currently in late-stage clinical trials. However, the identification of PKC412-resistant leukemic blast cells in the bone marrow of AML patients has propelled the development of novel and structurally distinct FLT3 inhibitors that have the potential to override drug resistance and more efficiently prevent disease progression or recurrence.